Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
25.78
-0.45 (-1.72%)
Nov 21, 2024, 1:03 PM EST - Market open
Zai Lab Revenue
Zai Lab had revenue of $102.27M in the quarter ending September 30, 2024, with 47.72% growth. This brings the company's revenue in the last twelve months to $355.75M, up 35.01% year-over-year. In the year 2023, Zai Lab had annual revenue of $266.72M with 24.03% growth.
Revenue (ttm)
$355.75M
Revenue Growth
+35.01%
P/S Ratio
7.19
Revenue / Employee
$163,562
Employees
2,175
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardent Health Partners | 5.71B |
| QuidelOrtho | 2.82B |
| Privia Health Group | 1.72B |
| iRhythm Technologies | 560.03M |
| Catalyst Pharmaceuticals | 460.48M |
| Protagonist Therapeutics | 323.80M |
| Twist Bioscience | 312.97M |
| Janux Therapeutics | 13.05M |
ZLAB News
- 9 hours ago - Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam) - Business Wire
- 3 days ago - Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - Business Wire
- 6 days ago - Zai Lab Announces Pricing of Public Offering of American Depositary Shares - Business Wire
- 7 days ago - Zai Lab Announces Proposed Public Offering of American Depositary Shares - Business Wire
- 9 days ago - Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates - Business Wire
- 10 days ago - Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Business Wire
- 23 days ago - Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China - Business Wire